Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Genitourinary Cancers
•
Medical Oncology
What's your choice of next line therapy for a metastatic papillary RCC who has progressed on cabozantinib?
Answer from: Medical Oncologist at Community Practice
Combination immunotherapy works well.
Sign in or Register to read more
15923
Related Questions
How do you manage anemia associated with belzutifan therapy?
Do you routinely continue patients on anti-PD(L)-1 beyond 2 years of treatment while on IO/TKI for metastatic ccRCC?
Would you consider enfortumab vedotin + pembrolizumab prior to surgery for a patient with urothelial carcinoma with regional nodes who is not eligible for neoadjuvant cisplatin?
When do you start ADT for a patient with a new diagnosis of node positive prostate cancer receiving radiation?
Would you recommend "adjuvant" immunotherapy in a older, frail patient who received radiation for upper tract urothelial carcinoma?
Would you prescribe semaglutide for weight gain from androgen deprivation therapy for prostate cancer?
How do you manage critically ill poor risk mixed germ cell tumor patients presenting de novo with extensive lung metastases and severe respiratory failure?
How do you manage prostate cancer in patients that cannot swallow pills?
Which patients, if any, do you offer transdermal estradiol as a method of ADT instead of LHRH agonists?
Which patients with prostate cancer do you consider to be good candidates for salvage local treatment after radiation therapy?